MAPT and Alzheimer disease: All comparisons remained statistically significant for CAP1DMN, CAP3ECN iNPH‐HC differences and CAP2VSM, CAP3ECN pre‐/post‐CSF tap test differences (Table 2), indicating that AD amyloid and tau pathologies do not drive our results.